Background: The aim of this study was to determine the characteristics of drug adherence in antidepressant-treated versus antidepressant-naïve patients using Drug Attitude Inventory (DAI)-10 scores for nonadherence, to examine the contribution of patient variables such as age, gender, education, prescription contents, side effects, and type of depression (melancholic, nonmelancholic, bipolar) to the reported DAI-10 score, and to examine the efficacy of pharmacist adherence instruction on adherence with antidepressant therapy.
Methods: The subjects were 71 antidepressant-treated inpatients (17 with melancholic depression, 35 with nonmelancholic depression, and 19 with bipolar depression) and 80 antidepressant-naïve inpatients. In the antidepressant-treated patients, self-management of drug intake and pharmacist adherence instruction was initiated after depressive symptoms were in remission, and pharmacist adherence instruction was conducted until the day of discharge.
Results: There were no significant differences in baseline characteristics between antidepressant-naïve and antidepressant-treated patients. In antidepressant-treated patients, the mean DAI-10 total score was significantly lower and awareness of side effects was significantly higher than in antidepressant-naïve patients who have never taken antidepressants, nor been referred to psychiatry services (according to pharmacist interviews and medical records). On the first day of self-management of drug intake, the DAI-10 total score in patients with melancholic and bipolar depression was significantly lower than that in patients with nonmelancholic depression. On the day of discharge, there was a significant improvement of DAI-10 total score in all antidepressant-treated patients, and the DAI-10 total score in patients with melancholic depression was significantly lower than that in patients with nonmelancholic depression. The limitation of the study was the small sample size and the fact that we followed only acute phase inpatients. However, the findings seem particularly robust in view of this.
Conclusion: Risk factors for nonadherence included side effects of antidepressant treatment and type of depression. The results presented here suggest that patients with melancholic depression may be more vulnerable to nonadherence, and that pharmacist adherence instruction may improve nonadherence in antidepressant-treated patients according to type of depression.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3526883 | PMC |
http://dx.doi.org/10.2147/PPA.S36295 | DOI Listing |
Neuroimage Clin
December 2024
Department of Neurology, Centre for Leading Medicine and Advanced Technologies of IHM, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui 230001, China. Electronic address:
Exploring the causal relationship between focal brain lesions and post-stroke depression (PSD) can provide therapeutic insights. However, a gap exists between causal and therapeutic information. Exploring post-stroke brain repair processes post-stroke could bridge this gap.
View Article and Find Full Text PDFMol Psychiatry
October 2024
MOODS Team, INSERM UMR 1018, CESP, Faculté de Médecine, Univ Paris-Saclay, Le Kremlin Bicêtre, F-94275, France.
Major Depressive Disorder (MDD) is the leading cause of disability worldwide. Genetic factors influence the effect of its main treatment option, antidepressant drugs (ATD). The GRIK4 rs1954787(T>C) genetic polymorphism was associated with response following 1-3 months of ATD treatment in some studies, but not others.
View Article and Find Full Text PDFClin Nutr ESPEN
October 2024
Department of Affective and Psychotic Disorders, Medical University of Lodz, 8/10 Czechoslowacka St., 92-216 Lodz, Poland. Electronic address:
Background & Aims: There is a need to identify new treatment options for depression with its comorbidities. Depression often coexists with liver steatosis and the two may share a pathophysiological overlap, including inflammation and microbiota changes. Probiotics might represent a safe option as an adjunctive therapy in patients with depression and possible liver steatosis.
View Article and Find Full Text PDFNutrients
May 2024
Department of Affective and Psychotic Disorders, Medical University of Lodz, Czechoslowacka Street 251, 92-216 Lodz, Poland.
Probiotics may represent a safe and easy-to-use treatment option for depression or its metabolic comorbidities. However, it is not known whether metabolic features can influence the efficacy of probiotics treatments for depression. This trial involved a parallel-group, prospective, randomized, double-blind, controlled design.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!